+1-888-308-5802     
News Contact Us

Novartis announces Kymriah’s EU approval for blood cancer treatment

Author : Pankaj Singh | Published Date : 2018-08-27 

Novartis International AG has reportedly announced that it has received approval for its cancer therapy called Kymriah, issued by the European Commission. The approved gene-modifying treatment will be used initially to treat young adults up to 25 years of age suffering with B-Cell acute lymphoblastic leukemia and adult patients down with diffuse large B-cell lymphoma.

The one-time therapy that’s said to treat blood cancer by fighting T-cells in the patient’s system, will supposedly modify their bodies to fight off bad cells and then re-infuse new cells. The treatment is also approved in both indications in the United States.

According to sources close to the development, with an investment of $90.39 million Novartis will establish more facilities to continue manufacturing Kymriah. The pharma claimed therapy will cost about $475,000 for patients with acute lymphoblastic leukemia and $373,000 for patients afflicted with diffuse large B-cell lymphoma.

Formerly, Novartis had gained appreciation for its groundbreaking work pertaining to therapy exclusively for dying patients who didn’t respond to other drugs. However, officials were aghast by the prices, which apparently makes Kymriah one of the most expensive treatments.

In the United States, Novartis will only accept charges if patients with lymphoblastic leukemia show signs of recovery by the end of the first month. Meanwhile, discussions in terms of European pricing are still in progress.

In a statement to sources, Novartis revealed that Kymriah’s availability will differ for each country, based on factors like the establishment of licensed facilities for the appropriate indications and completion of a fixed payment agreement.

Post its launch in the United States, the treatment earned $28 million in sales, which is estimated to surpass $1 billion as soon as the demand begins to grow. In the meantime, the pharma firm plans to commence therapies to European patients at least by 2020.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Royal Dutch Shell’s India unit opens first lubricant lab in India

Published Date: 2019-05-22         Author: Pankaj Singh

Royal Dutch Shell’s India unit has recently announced that the company has opened its first lubricant laboratory in Bengaluru, its technological center. The company plans to expand its Research and Development (R&D) efforts for the country, as well as internationally, reports source. Sh... Read More

SRF Ltd announces to sell engineering plastics business to DSM

Published Date: 2019-05-14         Author: Pankaj Singh

SRF has commercial interests in more than 75 countries and has a global workforce of 6,500 people. Specialty chemical manufacturing company SRF Ltd has reportedly settled on to selling its engineering plastics business to the Indian unit of Royal DSM for INR 320 crore ($45.6 million). The balance... Read More

Mondelez Inc. may manufacture CBD-infused snacks and cookies

Published Date: 2019-05-04         Author: Pankaj Singh

Professional chefs have termed cannabis- and CBD-infused food as the top food trend of the year 2019. The American multinational confectionary company Mondelez Inc. is reportedly planning to include CBD-infused snacks in its line of products, which includes Cadbury chocolate, Chips Ahoy cookies, ... Read More

© 2019 Fractovia. All Rights Reserved